Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.ncbi.nlm.nih.gov › pmc › articlesThe SATURN trial: the value of maintenance erlotinib in patients...

   www.ncbi.nlm.nih.gov › pmc › articles

   The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...

   • Figure 3

     The first-line treatment of advanced non-small-cell lung...

2. ascopubs.org › doi › 10Systemic and tumor-directed therapy for oligorecurrent metastatic...

   ascopubs.org › doi › 10

   29 Ιαν 2024 · Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial. Authors : John Nikitas , Matthew Rettig , John Shen , Robert Evan Reiter , Alan Lee , Michael L. Steinberg , Luca Faustino Valle , …

3. pubmed.ncbi.nlm.nih.gov › 21142856The SATURN trial: the value of maintenance erlotinib in ... -...

   pubmed.ncbi.nlm.nih.gov › 21142856

   The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.

4. www.researchgate.net › publication › 343872988_SATURN_A_double-blind_randomizedSATURN: A double-blind, randomized, phase III study of...

   www.researchgate.net › publication › 343872988_SATURN_A_double-blind_randomized

   20 Μαΐ 2009 · SATURN (Sequential Tarceva in Unresectable NSCLC) 73 is a randomized, placebo-controlled phase III trial in which erlotinib was evaluated as first-line maintenance therapy in advanced NSCLC ...

5. ascopubs.org › doi › pdfProspective Molecular Marker Analyses of EGFR and KRAS From a ...

   ascopubs.org › doi › pdf

   3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended progression-free survival (PFS) and overall survival in patients with advanced non–small-cell lung cancer (NSCLC) who had nonprogressive disease following first-line platinum-doublet ...

6. www.thelancet.com › journals › lanoncErlotinib as maintenance treatment in advanced non-small-cell...

   www.thelancet.com › journals › lanonc

   20 Μαΐ 2010 · We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-progressive disease following first-line platinum-doublet chemotherapy.

7. www.ncbi.nlm.nih.gov › pmc › articlesEfficacy and safety of erlotinib in the treatment of metastatic...

   www.ncbi.nlm.nih.gov › pmc › articles

   20 Δεκ 2010 · Recently, Cappuzzo et al 50 presented data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial a double-blind, randomized, phase III study of maintenance erlotinib vs placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. The final results of the study found that the median OS ...